NASDAQ: ARQTArcutis Biotherapeutics Inc Stock Ownership - Who owns Arcutis Biotherapeutics?
Insider buying vs selling
Have Arcutis Biotherapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Patrick Burnett | Reporting Persons Title Executive Vice President and Chief Medical Officer | 2026-02-04 | 9,794 | $25.81 | $252.74kSell |
| Masaru Matsuda | Reporting Persons title SVP General Counsel and Corporate Secretary | 2026-02-02 | 4,714 | $25.63 | $120.82kSell |
| Latha Vairavan | SVP Chief Financial Officer | 2026-02-02 | 1,320 | $25.50 | $33.66kSell |
| Patrick Burnett | Reporting Persons Title Executive Vice President and Chief Medical Officer | 2026-02-02 | 3,675 | $25.50 | $93.71kSell |
| Larry Todd Edwards | Reporting Persons title EVP Chief Commercial Officer | 2026-02-02 | 2,052 | $25.50 | $52.32kSell |
| Howard G. Welgus | Director | 2026-02-02 | 10,000 | $25.05 | $250.48kSell |
| Masaru Matsuda | Reporting Persons title SVP General Counsel and Corporate Secretary | 2026-02-02 | 7,983 | $25.50 | $203.55kSell |
| Masaru Matsuda | Reporting Persons title SVP General Counsel and Corporate Secretary | 2026-02-02 | 8,562 | $24.97 | $213.79kSell |
| Masaru Matsuda | Reporting Persons title SVP General Counsel and Corporate Secretary | 2026-02-02 | 19,379 | $25.24 | $489.13kSell |
| Todd Watanabe | Reporting Persons title President and Chief Executive Officer | 2026-02-02 | 19,833 | $25.50 | $505.70kSell |
ARQT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ARQT insiders and whales buy or sell their stock.
ARQT Shareholders
What type of owners hold Arcutis Biotherapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Patrick J. Heron | 15.86% | 19,430,454 | $506.75M | Insider |
| Jennison Associates LLC | 10.00% | 12,254,119 | $319.59M | Institution |
| Rubric Capital Management LP | 8.78% | 10,749,457 | $280.35M | Institution |
| Suvretta Capital Management LLC | 8.55% | 10,478,000 | $273.27M | Institution |
| Frazier Life Sciences Management LP | 8.06% | 9,874,511 | $257.53M | Institution |
| Frazier Life Sciences VIII LP | 7.22% | 8,838,534 | $230.51M | Insider |
| Blackrock Inc | 7.00% | 8,573,995 | $223.61M | Institution |
| Vanguard Group Inc | 5.83% | 7,146,090 | $186.37M | Institution |
| Polar Capital Holdings PLC | 4.33% | 5,298,754 | $138.19M | Institution |
| State Street Corp | 3.79% | 4,641,315 | $121.05M | Institution |
ARQT vs Biotech Stocks
Arcutis Biotherapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.